| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 18.63 | 7.0% | 3.0% |
| Total Income | 18.63 | 7.0% | 3.0% |
| Expenditure | 44.66 | 3.1% | 29.1% |
| PBT | -16.57 | 49.7% | 70.1% |
| Net Profit | -16.57 | 49.7% | 70.8% |
| OPM | — | ||
| NPM | -88.90% | ||
| EPS | -0.11 | 47.6% | 78.0% |
ADC Therapeutics Reports Q2 2026 Financial Results and Provides Operational Updates
13 Aug 2026 · 13 Aug, 6:48 pm
Summary
ADC Therapeutics reported second quarter 2026 financial results, with net product revenue reaching $18.6 million, up slightly year-over-year. Total revenue for the six-month period was $40.1 million, down from $41.9 million in the prior year, largely due to a prior-year milestone payment. The company significantly reduced its net loss to $16.6 million in Q2 2026 from $56.6 million in Q2 2025, driven by a decrease in total operating expenses, particularly in R&D. Management highlighted continued commercial momentum and strong operational discipline through cost reduction efforts, with an expected cash runway into 2028.
Key Highlights
- 1
Second quarter 2026 net product revenue was $18.6 million, a slight increase from $18.1 million in the same period of 2025.
- 2
For the six months ended June 30, 2026, total revenue was $40.1 million, a decrease from $41.9 million in the prior year period, primarily due to a prior-year milestone.
- 3
Total operating expenses decreased significantly to $44.7 million in Q2 2026 from $63.0 million in Q2 2025, driven by lower R&D expenses.
- 4
Net loss for the second quarter of 2026 was $16.6 million, a substantial improvement from a net loss of $56.6 million in the second quarter of 2025.
- 5
The company reported cash and cash equivalents of $219.1 million as of June 30, 2026, with an expected cash runway at least into 2028.
- 6
Enrollment in the LOTIS-7 trial has been completed, and data supports the combination of ZYNLONTA plus glofitamab for 2L+ DLBCL.
- 7
The company announced a strategic reorganization, including a 17 percent workforce reduction, estimating annualized cost savings of approximately $10 million.
Management Comments
Ameet Mallik
We are pleased by our second quarter performance, which reflects continued commercial momentum and strong operational discipline through ongoing cost reduction efforts. Over the course of this year, we have released LOTIS-5 data and completed the LOTIS-7 trial. With these data now in hand, we believe that ZYNLONTA plus glofitamab offers an opportunity to take a leading second-line plus position, in the context of the evolving competitive landscape, solidifying ZYNLONTA as a foundational therapy in DLBCL. Additionally, following the FDA pre-sBLA meeting for the LOTIS-5 trial, we are assessing regulatory approaches to determine the best path forward.
Mohamed Zaki
As we work to advance ZYNLONTA into earlier lines of DLBCL, we remain confident that ZYNLONTA will continue to play a meaningful role for patients with B-cell malignancies, in the 3L+ DLBCL setting, and through potential compendia inclusion starting in 2027. We look forward to the presentation of the LOTIS-5, LOTIS-7 and MZL investigator-initiated trial data later this year and expect submission for publication. In addition, we expect to submit LOTIS-7 and MZL data to the FDA for Breakthrough Designation.
Informational and educational content only. Not investment advice.